Denosumab

• CAT Number: I043755
• CAS Number: 615258-40-7
• Molecular Formula: C6404H9908N1724O2004S50
• Molecular Weight: 144716.86
• Purity: ≥95%

Denosumab is a human monoclonal antibody binding to, and inhibiting, the receptor activator of RANKL (TNFSF11). Denosumab can reduce the risk of vertebral, nonvertebral and hip fractures[1], also has anti-cancer activity[2].

Reference

[1]. Moen MD, et al. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28(1):63-82.
 [Content Brief]

[2]. Chawla S, et al. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019;20(12):1719-1729.
 [Content Brief]